LINC01443: A Potential Drug Target and Biomarker (G400644)

Target Name: LINC01443

NCBI ID: G400644

LINC01443

Other Name(s): Long intergenic non-protein coding RNA 1443 | long intergenic non-protein coding RNA 1443

LINC01443: A Potential Drug Target and Biomarker

Introduction

LINC01443 is a non-protein coding RNA (ncRNA) molecule located within the intron of the gene ZNF21. ZNF21 is a key regulator of stem-cell proliferation and has been implicated in a variety of diseases, including cancer. LINC01443 has been identified as a potential drug target and biomarker due to its unique expression patterns and biological functions.

Structure and Expression

LINC01443 is a 24.8 kilobase (kb) RNA molecule with a single exon and a unique 5' end. It is expressed in a variety of tissues and cells, including stem cells, tissues, and organs. LINC01443 has been shown to be highly expressed in human pluripotent stem cells (iPSCs), making it a promising candidate for drug development.

Expression Patterns

LINC01443 has been shown to be highly expressed in various tissues and cells, including pluripotent stem cells, cancer cells, and tissues derived from brain tumors. It has been shown to be expressed in the brain and has been implicated in the development and progression of various neurological diseases, including Alzheimer's disease and Parkinson's disease.

Drug Interaction with LINC01443

Due to its unique expression patterns and biological functions, LINC01443 has been identified as a potential drug target. Drugs that target LINC01443 have the potential to inhibit its activity and potentially treat diseases associated with its overexpression.

One approach to targeting LINC01443 is to use small molecules that specifically interact with the RNA molecule. Drugs that have been shown to interact with LINC01443 include:

1. Small Molecules: Drugs that interact with LINC01443 have been identified using a variety of techniques, including high-throughput screening and bioinformatics analysis. These drugs have the potential to inhibit LINC01443's activity and treat diseases associated with its over-expression.
2. Antibodies: Antibodies that are specific for LINC01443 have been developed and used to treat a variety of diseases, including cancer. These antibodies have the potential to interact with LINC01443 and inhibit its activity.

Biomarker Potential

LINC01443 has also been identified as a potential biomarker for a variety of diseases, including cancer. Its unique expression patterns and biological functions make it an attractive candidate for use as a biomarker.

One approach to using LINC01443 as a biomarker is to use it as a gene expression marker to diagnose or monitor the progression of various diseases. For example, LINC01443 has been shown to be highly expressed in cancer cells and has been used as a biomarker for cancer diagnosis and treatment.

Conclusion

LINC01443 is a non-protein coding RNA molecule with unique expression patterns and biological functions. Its potential as a drug target and biomarker makes it an attractive candidate for further study and development. Further research is needed to fully understand the unique mechanisms of LINC01443 and its potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1443

The "LINC01443 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01443 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets